APOMINE apomorphine hydrochloride hemihydrate 100 mg/20 mL solution for infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

apomine apomorphine hydrochloride hemihydrate 100 mg/20 ml solution for infusion vial

interpharma pty ltd - apomorphine hydrochloride hemihydrate, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; sodium chloride; hydrochloric acid; water for injections - indicated to reduce the number and severity of ?off? phases in patients with parkinson?s disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during ?on? phases.

MOVAPO PFS apomorphine hydrochloride hemihydrate 50mg/10mL solution for subcutaneous infusion pre-filled syringe Australia - English - Department of Health (Therapeutic Goods Administration)

movapo pfs apomorphine hydrochloride hemihydrate 50mg/10ml solution for subcutaneous infusion pre-filled syringe

stada pharmaceuticals australia pty ltd - apomorphine hydrochloride hemihydrate, quantity: 50 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; hydrochloric acid - movapo pfs is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine injection should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.

APOMORPHINE WOCKHARDT apomorphine hydrochloride hemihydrate 10 mg/mL solution for injection or infusion ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

apomorphine wockhardt apomorphine hydrochloride hemihydrate 10 mg/ml solution for injection or infusion ampoule

wockhardt bio pty ltd - apomorphine hydrochloride hemihydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; sodium hydroxide; hydrochloric acid; water for injections - apomorphine wockhardt solution for injection or infusion is indicated to reduce the number and severity of ?off? phases in patients with parkinson?s disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during ?on? phases.

MOVAPO apomorphine hydrochloride hemihydrate 50 mg/5 mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

movapo apomorphine hydrochloride hemihydrate 50 mg/5 ml injection ampoule

stada pharmaceuticals australia pty ltd - apomorphine hydrochloride hemihydrate, quantity: 50 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium hydroxide; hydrochloric acid - movapo is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with movapo should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.

MOVAPO apomorphine hydrochloride hemihydrate 20 mg/2mL injection ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

movapo apomorphine hydrochloride hemihydrate 20 mg/2ml injection ampoule

stada pharmaceuticals australia pty ltd - apomorphine hydrochloride hemihydrate, quantity: 20 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium hydroxide; hydrochloric acid - movapo is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with movapo should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.

APOMINE Intermittent apomorphine hydrochloride hemihydrate 30mg/3mL injection cartridge Australia - English - Department of Health (Therapeutic Goods Administration)

apomine intermittent apomorphine hydrochloride hemihydrate 30mg/3ml injection cartridge

interpharma pty ltd - apomorphine hydrochloride hemihydrate, quantity: 10 mg - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium hydroxide; hydrochloric acid - apomorphine injection is indicated to reduce the number and severity of "off" phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine injection should be undertaken by a specialist unit in a hospital setting. conventional therapy should be continued during "on" phases.

APOWOK apomorphine hydrochloride hemihydrate 10 mg/mL solution for injection or infusion ampoule Australia - English - Department of Health (Therapeutic Goods Administration)

apowok apomorphine hydrochloride hemihydrate 10 mg/ml solution for injection or infusion ampoule

wockhardt bio pty ltd - apomorphine hydrochloride hemihydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; sodium hydroxide; hydrochloric acid; water for injections - apowok solution for injection or infusion is indicated to reduce the number and severity of ?off? phases in patients with parkinson?s disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during ?on? phases.

MOVAPO PEN apomorphine hydrochloride hemihydrate 30 mg/3 mL Solution for Injection, Cartridge Australia - English - Department of Health (Therapeutic Goods Administration)

movapo pen apomorphine hydrochloride hemihydrate 30 mg/3 ml solution for injection, cartridge

stada pharmaceuticals australia pty ltd - apomorphine hydrochloride hemihydrate, quantity: 30 mg - injection, solution - excipient ingredients: sodium metabisulfite; hydrochloric acid; water for injections - movapo pen is indicated to reduce the number and severity of 'off' phases in patients with parkinson's disease severely disabled by motor fluctuations refractory to conventional therapy. initiation of therapy with apomorphine should be undertaken in a specialist unit in a hospital setting. conventional therapy should be continued during 'on' phases.

Apomorphine hydrochloride 5mg/ml solution for infusion Ireland - English - HPRA (Health Products Regulatory Authority)

apomorphine hydrochloride 5mg/ml solution for infusion

pharmaceuticals sales & development sweden ab (pharmswed) - apomorphine hydrochloride hemihydrate - solution for infusion - 5 milligram(s)/millilitre - dopamine agonists; apomorphine

Apomorphine hydrochloride 5 mg/ml solution for infusion Ireland - English - HPRA (Health Products Regulatory Authority)

apomorphine hydrochloride 5 mg/ml solution for infusion

evolan pharma ab - apomorphine hydrochloride hemihydrate - solution for infusion - 5 milligram(s)/millilitre - dopamine agonists; apomorphine